Publications by authors named "Bringiotti R"

Background: Data on the potential association between diverticulosis and colonic neoplastic lesions are still controversial. We investigated this issue in subjects who underwent screening colonoscopy.

Methods: We reviewed the data of subjects with a positive fecal immunological test who underwent a first colonoscopy in the national colorectal screening program.

View Article and Find Full Text PDF

The diagnostic work-up in iron deficiency anaemia (IDA) patients can be challenging when bleedings or malabsorption are not clinically manifest. Lesions on the small bowel mucosa may cause IDA. We evaluated the prevalence of lesions on the small bowel mucosa detected at Videocapsule Endoscopy (VCE) in IDA patients following negative upper and lower endoscopies.

View Article and Find Full Text PDF

Malabsorptive disorders are closely associated with micronutrient deficiencies. In inflammatory bowel disease (IBD), trace element deficiencies pose a clinical burden from disease onset throughout its course, contributing to morbidity and poor quality of life. We aimed to conduct a systematic review and meta-analysis of the prevalence of zinc deficiency in IBD.

View Article and Find Full Text PDF

The intestinal microbiota, which has gained a foothold in the field of research, represents a significant factor for human health because of its ability to form relationships with the organism through the modulation of pathophysiological processes. Dysbiosis, which is caused by non-specific intestinal inflammation and leads to a condition of persistent low-grade inflammation, may be caused by poor eating habits and an unhealthy lifestyle, as well as psycho-physical stress and a sedentary lifestyle. Diet, prebiotics and probiotics, and moderate and aerobic exercise can, in order to increase well-being and reduce the chance of recurrence, all be deemed effective methods of improving gut-microbiota pretreatment or mitigating diseases or dysbiosis.

View Article and Find Full Text PDF

Background: Disease phenotype and outcome of late-onset Crohn's disease are still poorly defined.

Methods: In this Italian nationwide multicentre retrospective study, patients diagnosed ≥65 years (late-onset) were compared with young adult-onset with 16-39 years and adult-onset Crohn's disease 40-64 years. Data were collected for 3 years following diagnosis.

View Article and Find Full Text PDF

Currently, the diagnosis of psychiatric illnesses is based upon DSM-5 criteria. Although endophenotype-specificity for a particular disorder is discussed, the identification of objective biomarkers is ongoing for aiding diagnosis, prognosis, or clinical response to treatment. We need to improve the understanding of the biological abnormalities in psychiatric illnesses across conventional diagnostic boundaries.

View Article and Find Full Text PDF

Background & Aims: Infliximab (IFX) is an anti-tumor necrosis factor alpha agent used in inflammatory bowel diseases (IBD) therapy. Usually, it is administered over a 2-hour intravenous infusion. However, shortening the infusion duration to 1 hour has proved to be feasible and safe.

View Article and Find Full Text PDF

Inflammatory bowel diseases (IBDs), namely Crohn's disease and ulcerative colitis, are lifelong chronic disorders arising from interactions among genetic, immunological and environmental factors. Although the origin of IBDs is closely linked to immune response alterations, which governs most medical decision-making, recent findings suggest that gut microbiota may be involved in IBD pathogenesis. Epidemiologic evidence and several studies have shown that a dysregulation of gut microbiota (i.

View Article and Find Full Text PDF
Article Synopsis
  • Interferon-based therapies for HCV recurrence after liver transplantation have been largely ineffective and face safety issues with other treatments like boceprevir and telaprevir.
  • A study assessed the efficacy and safety of intravenous silibinin in 20 patients who did not respond to previous treatments; patients were randomly assigned to receive either silibinin or placebo.
  • Results showed that silibinin significantly reduced viral load after 14 days of treatment, was well tolerated with only minor side effects, and did not require adjustments to immunosuppressive medication levels.
View Article and Find Full Text PDF

Background: The recurrence of hepatitis C viral infection is common after liver transplant, and achieving a sustained virological response to antiviral treatment is desirable for reducing the risk of graft loss and improving patients' survival.

Aim: To investigate the long-term maintenance of sustained virological response in liver transplant recipients with hepatitis C recurrence.

Methods: 436 Liver transplant recipients (74.

View Article and Find Full Text PDF